Search bioRxiv⌕ Search

Biology subjects

Nasiri, F.

Publications and source records attributed to Nasiri, F..

3 recordsLinked to original sources

B-SMART-Former: An Explainable Transformer-Based Deep Learning Model for Predicting Drug-Drug Interactions Between Biotech and Small-Molecule Drugs

1Drug--drug interactions between biotech and small-molecule drugs play a critical role in medication safety and therapeutic efficacy. However, most existing computational DDI prediction methods focus primarily on interactions between small-molecule drugs, leaving biotech-small-molecule interactions comparatively underexplored. In this study, we propose B-SMART-Former, an explainable deep learning framework for predicting interaction types between biotech and small-molecule drugs. The proposed framework integrates ChemBERTa embeddings and Morgan molecular fingerprints for small molecules with ProtBERT embeddings for biotech drugs, eliminating the need for similarity-based features while leveraging complementary molecular representations. These multimodal features are processed by a hybrid architecture that combines Transformer-based self-attention, residual convolutional learning, and a multi-layer perceptron classifier to capture both global contextual dependencies and local discriminative patterns. The model is formulated as a multi-class classification task and evaluated using stratified 10-fold cross-validation. To improve model transparency, Integrated Gradients is employed as a post-hoc explainability method to identify the molecular features that contribute most strongly to each prediction. Experimental results demonstrate that B-SMART-Former achieves a micro-averaged AUROC of 0.9978 and an AUPR of 0.9682 while relying solely on intrinsic molecular representations, remaining competitive with similarity-based approaches. The proposed framework offers an effective and explainable solution for biotech-small-molecule DDI prediction and provides a practical foundation for future computational drug interaction studies.

bioinformatics↗

A Graph-Attention-Based Deep Learning Network for Predicting Biotech-Small-Molecule Drug Interactions

The increasing demand for effective drug combinations has made drug-drug interaction (DDI) prediction a critical task in modern pharmacology. While most existing research focuses on small-molecule drugs, the role of biotech drugs in complex disease treatments remains relatively unexplored. Biotech drugs, derived from biological sources, have unique molecular structures that differ significantly from those of small molecules, making their interactions more challenging to predict. This study introduces BSI-Net, a novel graph attention network-based deep learning framework that improves interaction prediction between biotech and small-molecule drugs. Experimental results demonstrate that BSI-Net outperforms existing methods in multi-class DDI prediction, achieving superior performance across various evaluation types, including micro, macro, and weighted assessments. These findings highlight the potential of deep learning and graph-based models in uncovering novel interactions between biotech and small-molecule drugs, paving the way for more effective combination therapies in drug discovery.

bioinformatics↗

mRNA-based vaccine candidate COReNAPCIN(R) induces robust humoral and cellular immunity in mice and non-human primates

At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for world-wide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving both of safety and highest level of clinical efficacy against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we provide preclinical report of COReNAPCIN(R); a vaccine candidate against SARS-CoV-2 infection. COReNAPCIN(R) is a nucleoside modified mRNA-based vaccine formulated in lipid nanoparticles (LNPs) for encoding the full-length prefusion stabilized SARS-CoV-2 spike glycoprotein on the cell surface. Vaccination of C57BL/6 and BALB/c mice and rhesus macaque with COReNAPCIN(R) induced strong humoral responses with high titers of virus-binding and neutralizing antibodies. Upon vaccination, a robust SARS-CoV-2 specific cellular immunity was also observed in both mice and non-human primate models. Additionally, vaccination protected rhesus macaques from symptomatic SARS-CoV-2 infection and pathological damage to the lung upon challenging the animals with high viral loads of up to 2x108 live viral particles. Overall, our data provide supporting evidence for COReNAPCIN(R) as a potent vaccine candidate against SARS-CoV-2 infection for clinical studies.

immunology↗